Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Sangamo, GE Healthcare

Premium
Sigma-Aldrich and Sangamo Ink Reagent Development Deal 
 
Sigma-Aldrich and Sangamo BioSciences this week announced an alliance to develop reagents based on Sangamo's zinc finger DNA-binding protein technology.
 
The companies said that the alliance combines Sigma's global marketing capabilities with Sangamo's expertise in the field of ZFPs.
 
Scientists at Sigma-Aldrich and Sangamo will use ZFP nucleases like precision "surgical instruments" to modify genes in cells and to develop and market ZFP products for broad use in reagent applications.
 
Among the anticipated applications are cell lines with enhanced protein production performance, panels of knock-out cell lines for drug discovery, and novel stem cell and transgenic animal models.
 

 
GE Healthcare Q2 Revenue, Profit Fall
 
General Electric this week said that second-quarter revenue for its Healthcare division slipped slightly as income declined 8 percent. GE Healthcare’s revenue for the three months ended June 30 dipped to $4.13 billion from $4.16 billion year over year.
 
GE Healthcare’s net earnings for the quarter dipped to $731 million from $795 million in the second quarter of 2006. GE did not break out its research and development expenses for the Healthcare segment.
 
GE's total revenues for the quarter were $42.3 billion, up from $37.7 billion during the same period last year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more